RxDoctor Payments Data

Christopher Jimenez, MD

Neurology · South Miami, FLNPI 1730509068

Payments from drug & device makers

$364,861in general payments, 2019–2025

Across 1,173 payments — averaging $311.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$248K
  • Novartis$52K
  • Sage Therapeutics, LLC$41K
  • AbbVie$3K
  • UCB, Inc.$3K
  • Lilly USA, LLC$1K
  • plus $17K from 54 others

What the payments were for

  • Speaking & faculty fees$1471%
  • Food & beverage$24,62699%
  • Education$1391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.6$248,090
Novartis46$51,511
Sage Therapeutics, LLC2$41,060
AbbVie(2 entities)201$3,474
UCB, Inc.74$2,845
Lilly USA, LLC56$1,159
Biogen51$1,144
Teva Pharmaceuticals USA, Inc.54$1,061
Mallinckrodt Hospital Products Inc.37$976
Pfizer53$950
SK Life Science, Inc.37$845
Eisai Inc.39$832
CSL Behring26$704
Neurocrine Biosciences, Inc.38$678
Argenx US, Inc.28$644
Amgen25$554
Otsuka America Pharmaceutical, Inc.23$549
Neurelis, Inc.21$541
Acadia Pharmaceuticals Inc29$534
Lundbeck LLC23$532
Amneal Pharmaceuticals LLC31$477
Takeda Pharmaceuticals U.S.A., Inc.15$388
Adamas Pharmaceuticals, Inc.24$387
Scilex Pharmaceuticals Inc.8$356
Kyowa Kirin, Inc.18$314
EMD Serono, Inc.16$308
AstraZeneca(2 entities)15$306
Almatica Pharma LLC12$295
TG Therapeutics, Inc.14$274
Acorda Therapeutics, Inc14$273
Biohaven Pharmaceuticals, Inc.13$273
Tanabe Pharma America, Inc.10$246
Sanofi12$239
MDD US Operations, LLC7$163
Biohaven Pharmaceutical Holding Company Ltd.7$126
Banner Life Sciences, LLC7$125
Aprecia Pharmaceuticals, LLC7$123
Upsher-smith Laboratories LLC6$123
Boston Scientific4$122
Merz Pharmaceuticals, LLC7$122
Avion Pharmaceuticals8$120
Johnson & Johnson(2 entities)4$89
Abbott4$85
Avanir Pharmaceuticals, Inc.5$84
Sunovion Pharmaceuticals Inc.4$74
Livanova USA, Inc.3$73
Cycle Pharmaceuticals Inc3$62
Alfasigma USA, Inc.3$61
Axsome Therapeutics, Inc.2$53
Genentech USA, Inc.2$47
Arbor Pharmaceuticals, Inc.2$36
ANI Pharmaceuticals, Inc.1$34
C2n Diagnostics, LLC2$34
Vanda Pharmaceuticals Inc.1$31
Life Molecular Imaging Ltd1$28
Alnylam Pharmaceuticals Inc.1$25
Octapharma USA, Inc.1$25
Xeris Pharmaceuticals, Inc.1$22
Azurity Pharmaceuticals, Inc.1$21
Impel Pharmaceuticals Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$364,861 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$722,440
Medicare patients
356
Services billed
13,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz13$645,115
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5024$175,225
NuplazidPimavanserin Tartrate29$140,891
HizentraImmun Glob G(Igg)/Pro/Iga 0-5014$114,508
RytaryCarbidopa/Levodopa38$57,937
RexultiBrexpiprazole21$42,072
Nurtec OdtRimegepant Sulfate14$31,694
NeuproRotigotine18$30,066
Ajovy AutoinjectorFremanezumab-Vfrm13$16,604
Lacosamide62$11,249
Memantine Hcl290$11,124
Gabapentin193$4,984
Carbamazepine ErCarbamazepine32$4,394
Pregabalin108$3,831
Memantine Hcl ErMemantine Hcl24$2,967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$306$645,11513 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$388$175,22524 claims
Acadia Pharmaceuticals IncNuplazid$534$140,89129 claims
CSL BehringHizentra$704$114,50814 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$477$60,72254 claims
Otsuka America Pharmaceutical, Inc.Rexulti$549$42,07221 claims
PfizerNurtec Odt$950$31,69414 claims
UCB, Inc.Neupro$2,845$30,06618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →